Q32 Bio Inc

Kalowski Lee’s recent $355k buy of Q32 Bio shares signals renewed insider confidence amid a strong rally and potential partnership news.

Q32 Bio insiders sell RSU‑triggered shares at $4.51; routine tax‑related sales keep the CEO, CFO and CSO’s long‑term stake strong amid a 13% monthly price climb.

Grayzel David S. exercises Q32 Bio’s newly granted stock option, adding 16,363 shares and signalling cautious long‑term confidence in the biotech’s gene‑correction platform.